A5017718040- Inflammatory mediators and NSAID effects
- Cancer Genomics and Diagnostics
- Fibroblast Growth Factor Research
- Genetic factors in colorectal cancer
- Helicobacter pylori-related gastroenterology studies
- Inflammatory Bowel Disease
- Nitric Oxide and Endothelin Effects
- Gastrointestinal motility and disorders
- Colorectal Cancer Treatments and Studies
- Drug Transport and Resistance Mechanisms
- Microscopic Colitis
Medical University of Vienna
2022-2025
Comprehensive Cancer Center Vienna
2025
Colitis is a major risk factor for the development of colorectal cancer, leading to colitis-associated cancer (CAC). The most commonly used animal model study CAC azoxymethane-dextran sulphate-sodium (AOM/DSS) model. ideal experimental conditions this depend on several factors, including mouse strain. No data feasibility and older mice, e.g., aging studies, have yet been reported. Thus, we conducted descriptive, observational pilot where was induced in 14-month-old female Balb/C C57/Bl6 mice...
Abstract Inhibition of the epidermal growth factor receptor (EGFR) shows clinical benefit in metastatic colorectal cancer (CRC) patients, but KRAS-mutations are known to confer resistance. However, recent reports highlight EGFR as a crucial target be co-inhibited with RAS inhibitors for effective treatment KRAS mutant CRC. Here, we investigated tumor cell-intrinsic contribution G12D tumors by establishing murine CRC organoids key mutations (KRAS, APC, TP53) and inducible deletion....
Introduction: The prostaglandin E 2 (PGE ) pathway is one of the main mediators intestinal inflammation. As activation calcium-sensing receptor (CaSR) induces expression inflammatory markers in colon, we assessed impact CaSR on PGE regulation colon cancer cells and vitro vivo . Methods Results: We treated CaSR-transfected HT29 Caco-2 cell lines with different orthosteric ligands or modulators measured gene levels. In CaSR-GFP cells, ligand spermine positive allosteric modulator NPS R -568...
The extracellular calcium-sensing receptor (CaSR) is a multifunctional proposed as possible drug target for inflammatory bowel disease. We showed previously that CaSR inhibition with NPS 2143, negative allosteric modulator of the CaSR, somewhat ameliorated symptoms chemically induced severe colitis in mice. However, it was unclear whether potential to reduce may have been overshadowed by severity inflammation our previous study. Therefore, we tested if could prevent medium-grade colitis....